DEVELOPMENT OF ENDOTHELIN-1 ANTAGONISTS

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$47,000.00
Award Year:
1991
Program:
SBIR
Phase:
Phase I
Contract:
n/a
Award Id:
16705
Agency Tracking Number:
16705
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
6200 Freeport Centre, Baltimore, MD, 21224
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
Sweetnam, Paul M
Principal Investigator
(301) 558-7000
Business Contact:
1 R43 HL46098-01
() -
Research Institute:
n/a
Abstract
ENDOTHELIN-1 (ET-1), A 21 AMINO ACID PEPTIDE, ACTING AT SPECIFIC RECEPTORS IN VASCULAR TISSUES HAS BEEN DEMONSTRATED TO INITIATE SUCH PHYSIOLOGICAL RESPONSES AS: DECREASES/INCREASES IN SYSTEMIC ARTERIAL PRESSURE, ALTERATIONS IN LOCAL BLOOD DISTRIBUTION, RENAL FUNCTION (I. E. FORMATION AND COMPOSITION OF URINE, RELEASE OF CIRCULATING HORMONES), AND DILATION/CONTRACTION OF NONVASCULAR SMOOTH MUSCLE (I. E. RESPIRATORY, GASTROINTESTINAL). IN ADDITION TO THESE PHYSIOLOGICAL ROLES ET-1 MAY ALSO BE INVOLVED IN SUCH DIVERSE FUNCTIONS AS INFLAMMATORY AND NEUROMODULATORY ACTION. ET-1 REGULATION OF CARDIOVASCULAR FUNCTION MAY PLAY A SIGNIFICANT ROLE IN CORONARY ANGINA AND CEREBRAL VASOSPASM, HYPERTENSION, AND ATHEROSCLEROSIS. WE WILL PERFORM THE IDENTIFICATION AND EVALUATION OF SYSTEMICALLY ACTIVE NON-PEPTIDE ANTAGONISTS OF ET-1 TO BE DEVELOPED AS NOVEL THERAPEUTIC APPROACHES FOR TREATING ANY OF THE DISORDERS MENTIONED ABOVE. STARTING WITH AN INVENTORY OF APPROXIMATELY 20,000 COMPOUNDS, IN VITRO RADIOLIGAND BINDING AND CALCIUM MOBILIZATION ASSAYS WILL SERVE AS INITIAL SCREENING PROCEDURES FOR IDENTIFYING SELECTIVE ET-1 ANTAGONISTS. LEAD STRUCTURES WILL THEN BE EVALUATED FOR ET-1-ANTAGONIST ACTIVITY IN VIVO USING CARDIOVASCULAR MONITORING. COMPOUNDS IDENTIFIED DURING PHASE I STUDIES WILL PROVIDE POINTS OF DEPARTURE FOR SYNTHETIC CHEMICAL IMPROVEMENTS DURING PHASE II WORK WITH CONTINUED EVALUATION OF COMPOUNDS FOR A CARDIOVASCULAR ACTIVITY AS WELL AS THE DEVELOPMENT OF ANIMAL MODELS NECESSARY TO ASSESS OTHER POTENTIAL THERAPEUTIC USES FOR AN ET-1 ANTAGONIST.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government